Stockscreener 앱 받기
25.84
2.33%
0.5879
Alumis Inc 주식(ALMS)의 최신 뉴스
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis Inc: Year-End 2025 Financial Results and Strategic TYK2 Pipeline Outlook - AlphaStreet
Why is ALMS stock rising today? - MSN
ALMS Price Today: Alumis Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Why Alumis Inc. Stock Is Surging Higher Now - TipRanks
ALMS Financials: Income Statement, Balance Sheet & Cash Flow | Alumis Inc - Stock Titan
Why Alumis Inc. Shares Are Surging Today - TipRanks
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March - MarketBeat
Saturn V Capital Management LP's Alumis Inc(ALMS) Holding History - GuruFocus
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target - TipRanks
H.C. Wainwright reiterates Alumis stock rating, $25 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Alumis stock rating, $25 target - Investing.com
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25 - Moomoo
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Raymond James and Guggenheim stay bullish on Alumis (ALMS) after trial results - MSN
Quarterly Earnings: Is Alumis Inc in a consolidation phaseProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
Alumis Inc. $ALMS Shares Sold by Trium Capital LLP - MarketBeat
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile - simplywall.st
ALUMIS INC. unveils psoriasis treatment isolating effects to immune cells only - Traders Union
Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS) - Stock Titan
Risk Analysis: Is Alumis Inc gaining market shareQuarterly Profit Review & High Return Trade Opportunity Guides - baoquankhu1.vn
Alumis Inc. (ALMS) stock price, news, quote and history - Yahoo Finance UK
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Yahoo Finance
Alumis (NASDAQ:ALMS) Shares Down 4.1%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Dropping After Good News - TipRanks
Form 8-KCurrent report - ADVFN
Why is Alumis stock falling Monday? - MSN
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - Sahm
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - MarketBeat
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - gurufocus.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
1.94%
1.54%
자본화:
|
볼륨(24시간):